daprodustat (Jesduvroq)

From Aaushi
Jump to navigation Jump to search

Indications

* not approved for patients not on renal dialysis

* patients must be on renal dialysis for at least 4 months[2]

Dosage

Mechanism of action

More general terms

References

  1. Singh AK et al. Daprodustat for the treatment of anemia in patients undergoing dialysis. N Engl J Med 2021 Dec 16; 385:2325 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34739194 https://www.nejm.org/doi/10.1056/NEJMoa2113379
    Singh AK et al. Efficacy and safety of daprodustat for treatment of anemia of chronic kidney disease in incident dialysis patients: A randomized clinical trial. JAMA Intern Med 2022 Apr 4; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/35377393 PMCID: PMC8981070 Free PMC article https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2790862
  2. 2.0 2.1 Monaco K FDA Panel Gives Thumbs Up to Anemia Pill for CKD Patients on Dialysis. But thumbs quickly turn down for the non-dialysis subset. MedPage Today October 27, 2022 https://www.medpagetoday.com/nephrology/anemia/101450
    Zoler ML FDA Approves Daprodustat, First Oral Anemia Treatment. Medscape. Feb 2, 2023 https://www.medscape.com/viewarticle/987789

Database